Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P23945

UPID:
FSHR_HUMAN

ALTERNATIVE NAMES:
Follitropin receptor

ALTERNATIVE UPACC:
P23945; A0A0A0MSC5; A8K947; G5CBS7; G5E967; J3KQ00; Q05AH0; Q16225; Q4QRJ3; Q4ZFZ2; Q53RW2

BACKGROUND:
The Follicle-stimulating hormone receptor, a key player in reproductive endocrinology, mediates the action of follitropin. This receptor's activation triggers essential signaling pathways, including PI3K-AKT and ERK1/ERK2, crucial for follicular development and gonadal function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Follicle-stimulating hormone receptor could open doors to potential therapeutic strategies for conditions like Ovarian dysgenesis 1 and Ovarian hyperstimulation syndrome, paving the way for advancements in fertility treatments and reproductive health management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.